Morgan Stanley
ARKG icon

Morgan Stanley’s ARK Genomic Revolution ETF ARKG Stock Holding History

Morgan Stanley’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$283M Buy
6,723,211
+1,868,295
+38% +$59.5M 0.02% 827
2026
Q1 		$128M Buy
4,854,916
+828,951
+21% +$24.3M 0.01% 1238
2025
Q4 		$117M Buy
4,025,965
+1,193,795
+42% +$35.8M 0.01% 1315
2025
Q3 		$78.6M Buy
2,832,170
+705,694
+33% +$17.8M ﹤0.01% 1623
2025
Q2 		$51.8M Sell
2,126,476
-238,538
-10% -$5.23M ﹤0.01% 1899
2025
Q1 		$49.1M Sell
2,365,014
-1,119,322
-32% -$28.1M ﹤0.01% 1830
2024
Q4 		$82M Buy
3,484,336
+2,070,903
+147% +$51M 0.01% 1405
2024
Q3 		$36.2M Sell
1,413,433
-124,207
-8% -$3.16M ﹤0.01% 2176
2024
Q2 		$36.1M Sell
1,537,640
-417,784
-21% -$10.5M ﹤0.01% 2049
2024
Q1 		$56.2M Buy
1,955,424
+355,979
+22% +$10.7M ﹤0.01% 1648
2023
Q4 		$52.5M Sell
1,599,445
-1,607,534
-50% -$43.7M ﹤0.01% 1674
2023
Q3 		$89.3M Sell
3,206,979
-169,366
-5% -$5.54M 0.01% 1132
2023
Q2 		$115M Sell
3,376,345
-790,887
-19% -$24.9M 0.01% 1003
2023
Q1 		$125M Buy
4,167,232
+561,518
+16% +$17.4M 0.01% 937
2022
Q4 		$102M Sell
3,605,714
-1,372,136
-28% -$43.5M 0.01% 1020
2022
Q3 		$164M Buy
4,977,850
+1,543,773
+45% +$56.7M 0.02% 659
2022
Q2 		$108M Sell
3,434,077
-753,457
-18% -$26.3M 0.01% 878
2022
Q1 		$192M Buy
4,187,534
+555,156
+15% +$26.5M 0.03% 545
2021
Q4 		$222M Sell
3,632,378
-108,161
-3% -$7.48M 0.03% 521
2021
Q3 		$279M Buy
3,740,539
+543,334
+17% +$45.6M 0.04% 418
2021
Q2 		$296M Sell
3,197,205
-164,583
-5% -$14M 0.04% 412
2021
Q1 		$298M Buy
3,361,788
+782,912
+30% +$77.7M 0.04% 360
2020
Q4 		$241M Buy
2,578,876
+648,974
+34% +$51.7M 0.04% 413
2020
Q3 		$123M Buy
1,929,902
+422,006
+28% +$24.7M 0.02% 525
2020
Q2 		$78.7M Buy
1,507,896
+346,329
+30% +$14.9M 0.02% 633
2020
Q1 		$36.3M Buy
1,161,567
+344,826
+42% +$11.5M 0.01% 896
2019
Q4 		$27.4M Buy
816,741
+155,904
+24% +$4.95M 0.01% 1384
2019
Q3 		$19.5M Buy
660,837
+53,380
+9% +$1.73M 0.01% 1506
2019
Q2 		$20.9M Buy
607,457
+66,549
+12% +$2.13M 0.01% 1450
2019
Q1 		$17.8M Buy
540,908
+69,022
+15% +$2.04M 0.01% 1523
2018
Q4 		$11.3M Sell
471,886
-52,812
-10% -$1.49M ﹤0.01% 1998
2018
Q3 		$17.5M Buy
524,698
+142,455
+37% +$4.51M ﹤0.01% 1820
2018
Q2 		$11.1M Buy
382,243
+130,043
+52% +$3.62M ﹤0.01% 2261
2018
Q1 		$6.49M Buy
252,200
+163,117
+183% +$4.42M ﹤0.01% 2746
2017
Q4 		$2.18M Buy
89,083
+55,586
+166% +$1.41M ﹤0.01% 3959
2017
Q3 		$879K Buy
33,497
+33,471
+128,735% +$787K ﹤0.01% 4513
2017
Q2 		$1K Buy
+26
New +$542 ﹤0.01% 6496

Other funds holding ARKG

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley's ARKG Position: Q2 2026 in Review

Morgan Stanley increased its ARK Genomic Revolution ETF (ARKG) stake by 38% in Q2 2026, buying an estimated $59.5M and bringing the position to 6,723,211 shares worth $283M. The position accounts for 0.02% of the portfolio, ranked #827.

Morgan Stanley first reported a position in ARKG in Q2 2017 and has held it in 37 quarters since. The position peaked at $298M in Q1 2021. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

  • Morgan Stanley held 6,723,211 shares of ARK Genomic Revolution ETF worth $283M as of Q2 2026.
  • Morgan Stanley bought 1,868,295 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $59.5M.
  • ARK Genomic Revolution ETF made up 0.02% of Morgan Stanley's portfolio in Q2 2026, its #827 holding.
  • Morgan Stanley first reported a position in ARK Genomic Revolution ETF in Q2 2017 and has held it in 37 quarters since.
  • Morgan Stanley's ARK Genomic Revolution ETF position peaked at $298M in Q1 2021.
  • 271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.